Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; [18F]MNI-946; [3H]MK 6240; Fluorine-18-MK6240; MK-6240

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; Molecular NeuroImaging
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 14 Sep 2017 Cerveau Technologies enters into a research collaboration with H. Lundbeck A/S for neurodegenerative diseases
  • 22 Aug 2017 Interim efficacy data from a phase I trial in Alzheimer’s disease presented at the Alzheimer's Association International Conference® 2017 (AAIC®)
  • 15 Jul 2017 Pharmacodynamic results from a preclinical study presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top